Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Conditions
Metastatic Hepatocellular Carcinoma · Solid Tumors · Solid Tumor, Adult · FGFR Gene Amplification · FGFR Gene Alterations · FGFR3 Gene Alteration · FGFR3 Gene Mutation · Advanced Solid Tumors · FGFR4 Gene Mutation · FGFR4 Gene Fusions · FGF19 Gene Amplification · FGF19 Gene Overexpression · FGFR3 Gene Fusions · Locally Advanced Unresectable Hepatocellular Carcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
UCSF Medical Center at Mount Zion, San Francisco, California, United States
Stanford Cancer Institute, Stanford, California, United States
The University of Kansas Medical Center, Westwood, Kansas, United States
John Hopkins University, Baltimore, Maryland, United States
Mass General Cancer Center, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Columbia University Irving Medical Center, New York, New York, United States
Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee, United States
University Health Network Princess Margaret Cancer Center, Toronto, Ontario, Canada
Asan Medical Center, Seoul, South Korea
Samsung Medical Center, Seoul, South Korea
Seoul National University Hospital, Seoul, South Korea
Severance Hospital, Yonsei University Health System, Seoul, South Korea
National Taiwan University Hospital, Taipei, Taiwan
Taipei Veterans General Hospital, Taipei, Taiwan
Study leads
Doug Warner, MD
Study Chair
Tyra Biosciences, Inc